To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A multicenter study
Örebro University, School of Medical Sciences.ORCID iD: 0009-0002-8951-9839
Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium; Department of Biotechnology, Kumaraguru College of Technology, Coimbatore, Tamil Nadu, India.
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology.ORCID iD: 0000-0002-1906-0746
Örebro University, School of Medical Sciences. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID iD: 0000-0002-6598-1984
Show others and affiliations
2024 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, article id jjae169Article in journal (Refereed) Epub ahead of print
Abstract [en]

BACKGROUND: Recent genetic and transcriptomic data highlight the need for improved molecular characterisation of inflammatory bowel disease (IBD). Proteomics may advance the delineation of IBD phenotypes since it accounts for post-transcriptional modifications. AIM: We aimed to assess the IBD spectrum based on inflammatory serum proteins and identify discriminative patterns of underlying biological subtypes across multiple European cohorts.

METHODS: Using proximity extension methodology, we measured 86 inflammation-related serum proteins in 1551 IBD patients and 312 healthy controls (HC). We screened for proteins exhibiting significantly different levels among IBD subtypes and between IBD and HC. Classification models for differentiating between Crohn's disease (CD) and ulcerative colitis (UC) were employed to explore the IBD spectrum based on estimated probability scores.

RESULTS: Levels of multiple proteins, such as IL-17A, MMP-10, and FGF-19, differed (fold-change>1.2; FDR<0.05) between ileal vs colonic IBD. Using multivariable models, a protein signature reflecting the IBD spectrum was identified, positioning colonic CD between UC and ileal CD, which were at opposite ends of the spectrum. Based on area under the curve (AUC) estimates, classification models more accurately differentiated UC from ileal CD (median AUCs>0.73) than colonic CD (median AUCs<0.62). Models differentiating colonic CD from ileal CD demonstrated intermediate performance (median AUCs 0.67-0.69).

CONCLUSION: Our findings in serum proteins support the presence of a continuous IBD spectrum rather than a clear separation of CD and UC. Within the spectrum, disease location may reflect a more similar disease than CD vs UC, as colonic CD resembled UC more closely than ileal CD.

Place, publisher, year, edition, pages
Oxford University Press, 2024. article id jjae169
Keywords [en]
Biomarkers, Crohn's disease, Montreal classification, Ulcerative colitis, disease location, serum proteins
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-117208DOI: 10.1093/ecco-jcc/jjae169ISI: 001377184400001PubMedID: 39495605OAI: oai:DiVA.org:oru-117208DiVA, id: diva2:1910636
Funder
Swedish Research Council, 020-02021Swedish Foundation for Strategic Research, B13-016Region Örebro County, LL-986849Region Örebro County, LL-974710Region Örebro County, 936004Region Örebro County, OLL-962042EU, Horizon 2020
Note

This study was supported by the Swedish Research Council (grant number 2020-02021 to Jonas Halfvarson), the Swedish Foundation for Strategic Research (grant number RB13-016 to Jonas Halfvarson), the Örebro University Hospital Research Foundation (grant numbers OLL-986849, OLL-974710, OLL-936004, and OLL-962042 to Jonas Halfvarson). This project has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Available from: 2024-11-05 Created: 2024-11-05 Last updated: 2025-01-17Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Salomon, BenitaBergemalm, DanielAndersson, ErikLindqvist, Carl MårtenKruse, RobertRepsilber, DirkHalfvarson, Jonas

Search in DiVA

By author/editor
Salomon, BenitaBergemalm, DanielAndersson, ErikLindqvist, Carl MårtenKruse, RobertRepsilber, DirkHalfvarson, Jonas
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Journal of Crohn's & Colitis
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 24 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf